Rein Therapeutics IncRNTX
Price$0.85

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
32.8%projected annual EPS growth
As of 27 Aug 2026
Analyst Coverage
2analysts covering
Consensus: PositiveAs of 18 Aug 2026
FY EPS (est.)
-$0.44next fiscal year
As of 18 Aug 2026
Reporting Calendar
EventExpected Date
Q3 2026 Earnings Release16 Nov 2026
Monitoring Framework
Key Performance Indicators
RENEW Phase 2 Trial Patient Enrollment Quarterly16.0
Watch Items
  • RENEW Phase 2 Trial Global Site ExpansionTrigger: Activation of clinical sites in two additional countriesAction: Monitor global enrollment momentum and regulatory approvals in newly added countries
Sign in / Sign up to read more

Research as of 20 Jun 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.